secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-040767
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%
--------------------------------------------------------------------------------

- Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.
- MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.
- Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.
- Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.
- Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/pyxs-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer